A study from PreciseDx showed that its artificial-intelligence-guided pathology test could help predict a patient’s chances of their breast cancer returning on par with a leading genomic approach. Working with real-world cancer data company...

PreciseDX: World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio NEW YORK, Nov. 20, 2024 /PRNewswire/...

NEW YORK – Cota, PreciseDx, and Baptist Health South Florida on Wednesday said they are collaborating to validate PreciseDx's PreciseBreast test to predict the likelihood of invasive breast cancer recurrence. Cota, which is based in...

PreciseDx: The poster presentation features findings from PreciseDx's collaboration with the Laboratory of Pathology, Dordrecht Albert Schweitzer Hospital in the Netherlands. NEW YORK, May 28, 2024 /PRNewswire/ -- PreciseDx®, a leading...

PreciseDx: Sponsored collaboration will focus on evaluating the ability of PreciseBreast™ to accurately predict breast cancer recurrence for those patients with TNBC  NEW YORK, April 2, 2024 /PRNewswire/ -- PreciseDx®, a leading...

In January of this year, in a major regulatory milestone, New York State Department of Health approved a new AI-based digital pathology diagnostic test for breast cancer. The test, developed by PreciseDx, is performed on tumor samples removed...